ClinicalTrials.gov
History of Changes for Study: NCT02041533
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Latest version (submitted February 2, 2023) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 January 19, 2014 None (earliest Version on record)
2 February 28, 2014 Study Status
3 March 26, 2014 Recruitment Status, Study Status and Contacts/Locations
4 April 29, 2014 Contacts/Locations, Study Status and References
5 May 7, 2014 Contacts/Locations and Study Status
6 May 27, 2014 Contacts/Locations and Study Status
7 May 30, 2014 Study Status
8 July 4, 2014 Contacts/Locations and Study Status
9 July 9, 2014 Contacts/Locations and Study Status
10 July 23, 2014 Contacts/Locations and Study Status
11 August 11, 2014 Contacts/Locations and Study Status
12 August 28, 2014 Contacts/Locations and Study Status
13 September 15, 2014 Contacts/Locations and Study Status
14 September 22, 2014 Contacts/Locations and Study Status
15 October 13, 2014 Contacts/Locations and Study Status
16 October 30, 2014 Contacts/Locations and Study Status
17 November 13, 2014 Contacts/Locations and Study Status
18 November 20, 2014 Contacts/Locations and Study Status
19 December 5, 2014 Contacts/Locations and Study Status
20 December 31, 2014 Contacts/Locations and Study Status
21 January 27, 2015 Contacts/Locations and Study Status
22 February 26, 2015 Contacts/Locations, Study Status and Sponsor/Collaborators
23 March 5, 2015 Contacts/Locations and Study Status
24 March 23, 2015 Contacts/Locations and Study Status
25 April 13, 2015 Contacts/Locations and Study Status
26 April 20, 2015 Contacts/Locations and Study Status
27 May 6, 2015 Contacts/Locations, Study Status and Study Design
28 May 20, 2015 Study Status
29 June 3, 2015 Study Status
30 June 22, 2015 Contacts/Locations and Study Status
31 July 3, 2015 Contacts/Locations and Study Status
32 July 17, 2015 Contacts/Locations and Study Status
33 August 4, 2015 Contacts/Locations and Study Status
34 August 18, 2015 Study Status
35 September 3, 2015 Contacts/Locations and Study Status
36 September 16, 2015 Contacts/Locations and Study Status
37 October 5, 2015 Recruitment Status, Contacts/Locations and Study Status
38 October 15, 2015 Study Status
39 November 4, 2015 Contacts/Locations and Study Status
40 November 18, 2015 Study Status
41 December 8, 2015 Study Status and Contacts/Locations
42 December 21, 2015 Study Status
43 January 6, 2016 Study Status
44 January 21, 2016 Study Status
45 January 26, 2016 Study Status
46 February 10, 2016 Study Status
47 February 25, 2016 Study Status
48 March 11, 2016 Study Status
49 March 28, 2016 Study Status
50 April 12, 2016 Study Status
51 April 21, 2016 Study Status
52 April 25, 2016 Study Status
53 May 10, 2016 Study Status
54 May 25, 2016 Study Status
55 June 9, 2016 Study Status
56 June 24, 2016 Study Status
57 July 11, 2016 Study Status
58 July 26, 2016 Study Status
59 August 8, 2016 Study Status
60 August 23, 2016 Study Status
61 September 15, 2016 Study Status
62 September 23, 2016 Study Status
63 October 7, 2016 Study Status
64 October 26, 2016 Study Status
65 November 8, 2016 Study Status
66 November 30, 2016 Study Status
67 December 6, 2016 Study Status
68 December 23, 2016 Study Status
69 January 5, 2017 Study Status
70 January 23, 2017 Contacts/Locations and Study Status
71 January 27, 2017 Study Status
72 February 16, 2017 Study Status
73 March 3, 2017 Study Status
74 March 29, 2017 Study Status
75 April 17, 2017 Contacts/Locations and Study Status
76 June 26, 2017 Study Status, Outcome Measures, Contacts/Locations, References, Study Design, Oversight and Results
77 July 25, 2017 Participant Flow and Study Status
78 January 18, 2018 Contacts/Locations and Study Status
79 August 21, 2019 Contacts/Locations, Study Status, References and Outcome Measures
80 November 15, 2019 Study Status and Contacts/Locations
81 December 10, 2019 Study Status
82 January 24, 2020 Study Status and Contacts/Locations
83 May 14, 2020 Study Status and Contacts/Locations
84 June 16, 2020 Study Status
85 July 6, 2020 Contacts/Locations and Study Status
86 June 9, 2021 Contacts/Locations and Study Status
87 March 8, 2022 Contacts/Locations, Study Status, References, Eligibility and Oversight
88 May 2, 2022 Study Status and Contacts/Locations
89 July 19, 2022 Recruitment Status, Study Status and Contacts/Locations
90 February 2, 2023 Adverse Events, Outcome Measures, Participant Flow, Baseline Characteristics, Contacts/Locations, Study Status, More Information and Study Design
Comparison Format:
Scroll up to access the controls
Study NCT02041533
Submitted Date:  July 3, 2015 (v31)
Open or close this module Study Identification
Unique Protocol ID: CA209-026
Brief Title: An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Official Title: An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Secondary IDs: 2012-004502-93 [EudraCT Number]
Open or close this module Study Status
Record Verification: May 2015
Overall Status: Recruiting
Study Start: March 2014
Primary Completion: August 2016 [Anticipated]
Study Completion: January 2018 [Anticipated]
First Submitted: January 19, 2014
First Submitted that
Met QC Criteria:		 January 19, 2014
First Posted: January 22, 2014 [Estimate]
Last Update Submitted that
Met QC Criteria:		 July 3, 2015
Last Update Posted: July 7, 2015 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Bristol-Myers Squibb
Responsible Party: Sponsor
Collaborators: Ono Pharmaceutical Co. Ltd
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
Detailed Description:
Open or close this module Conditions
Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 3
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 535 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Arm A: Nivolumab subjects
Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
 Biological: Nivolumab
Other Names:
  • BMS-936558
  • MDX-1106
Active Comparator: Arm B: Investigator's Choice Chemotherapy

Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first

Squamous subjects:

  • Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or
  • Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or
  • Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle

Non-Squamous subjects:

  • Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle
  • Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle

Optional crossover:

  • Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure
 Biological: Nivolumab
Other Names:
  • BMS-936558
  • MDX-1106
Drug: Gemcitabine
Other Names:
  • Gemzar
Drug: Cisplatin
Other Names:
  • Platinol
Drug: Carboplatin
Other Names:
  • Paraplatin
Drug: Paclitaxel
Other Names:
  • Taxol
Drug: Pemetrexed
Other Names:
  • Alimta
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Progression Free Survival (PFS) as assessed by independent radiology review committee (IRRC) in subjects with strongly Programmed death-ligand 1+ (PD-L1+) tumor expression
[ Time Frame: Up to approximately 33 months ]

PFS is defined as the time from randomization to the date of the first documented tumor progression as determined by the IRRC (per RECIST 1.1), or death due to any cause
Secondary Outcome Measures:
1. Objective response rate (ORR) as determined per IRRC in subjects with strongly PD-L1+ tumor expression
[ Time Frame: Up to approximately 33 months ]

ORR is defined as the number of subjects whose best confirmed objective response is a complete response (CR) or partial response (PR), divided by the number of randomized subjects among strongly PD-L1+ subjects
2. Overall survival (OS) in subjects with strongly PD-L1+ tumor expression
[ Time Frame: At least 33 months ]

OS is defined as the time from randomization to the date of death
3. PFS in all subjects with any PD-L1+ tumor expression
[ Time Frame: Up to approximately 33 months ]
4. Disease related symptom improvement in all subjects
[ Time Frame: Up to approximately 33 months ]

Disease-related symptom improvement rate is defined as the proportion of randomized subjects who had a disease-related symptom improvement as measured by the lung cancer symptom scale (LCSS) among all PD-L1+ subjects
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1
  • Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapy
  • Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteria
  • PD-L1+ on immunohistochemistry testing performed by central lab
  • Men and women, ages ≥ 18 years of age

Exclusion Criteria:

  • Known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy
  • Known anaplastic lymphoma kinase (ALK) translocations
  • Untreated central nervous system (CNS) metastases
  • Previous malignancies
  • Active, known or suspected autoimmune disease
Open or close this module Contacts/Locations
Central Contact Person: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:
Email: Clinical.Trials@bms.com
Central Contact Backup: First line of the email MUST contain NCT# and Site #.
Study Officials: Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Locations: United States, Alabama
Southern Cancer Center
[Active, not recruiting]
Mobile, Alabama, United States, 36608
United States, Arizona
Banner Md Anderson Cancer Center
[Active, not recruiting]
Gilbert, Arizona, United States, 85234
Arizona Oncology Associates
[Active, not recruiting]
Tucson, Arizona, United States, 85704
United States, California
Stanford Cancer Institute
[Active, not recruiting]
Stanford, California, United States, 94305
United States, Colorado
Anschutz Cancer Pavilion
[Active, not recruiting]
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University
[Active, not recruiting]
New Haven, Connecticut, United States, 06520
United States, Florida
Advanced Medical Specialties
[Active, not recruiting]
Miami, Florida, United States, 33176
Ocala Oncology Center
[Active, not recruiting]
Ocala, Florida, United States, 34471
H. Lee Moffitt Cancer Center
[Active, not recruiting]
Tampa, Florida, United States, 33612
United States, Georgia
Emory University - Winship Cancer Institute
[Active, not recruiting]
Atlanta, Georgia, United States, 30322
Northwest Georgia Oncology Center, P.C.
[Active, not recruiting]
Marietta, Georgia, United States, 30060
United States, Illinois
Rush University Med Ctr
[Completed]
Chicago, Illinois, United States, 60612
United States, Kentucky
Baptist Health Lexington
[Active, not recruiting]
Lexington, Kentucky, United States, 40503
United States, Louisiana
Crescent City Research Consortium, Llc
[Active, not recruiting]
Marrero, Louisiana, United States, 70072
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
[Active, not recruiting]
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Massachusetts General Hospital
[Active, not recruiting]
Boston, Massachusetts, United States, 02114
Beth Isreael Deaconess Medical Center
[Active, not recruiting]
Boston, Massachusetts, United States, 02215
United States, New York
Roswell Park Cancer Institute
[Active, not recruiting]
Buffalo, New York, United States, 14263
Laura And Isaac Perlmutter Cancer Center
[Active, not recruiting]
New York, New York, United States, 10016
Memorial Sloan Kettering Cancer Center
[Active, not recruiting]
New York, New York, United States, 10065
United States, North Carolina
University Of North Carolina At Chapel Hill
[Active, not recruiting]
Chapel Hill, North Carolina, United States, 27599
Duke University Medical Center
[Active, not recruiting]
Durham, North Carolina, United States, 27710
United States, Ohio
University Hospitals Of Cleveland
[Active, not recruiting]
Cleveland, Ohio, United States, 44106
The Ohio State University
[Active, not recruiting]
Columbus, Ohio, United States, 43210
United States, Oregon
Oregon Health & Science University
[Active, not recruiting]
Portland, Oregon, United States, 97239
United States, Pennsylvania
Network Office Of Research And Innovation
[Active, not recruiting]
Allentown, Pennsylvania, United States, 18103
University Of Pennsylvania
[Active, not recruiting]
Philadelphia, Pennsylvania, United States, 19104
Fox Chase Cancer Center
[Active, not recruiting]
Philadelphia, Pennsylvania, United States, 19111
Upmc Cancer Pavilion
[Active, not recruiting]
Pittsburgh, Pennsylvania, United States, 15232
United States, South Carolina
Hollings Cancer Center
[Active, not recruiting]
Charleston, South Carolina, United States, 29425
St Francis Hospital
[Active, not recruiting]
Greenville, South Carolina, United States, 29601
United States, Tennessee
Vanderbilt-Ingram Cancer Ctr
[Active, not recruiting]
Nashville, Tennessee, United States, 37232
United States, Texas
University Of Texas Southwestern Medical Center
[Active, not recruiting]
Dallas, Texas, United States, 75390
The University Of Texas Md Anderson Cancer Center
[Active, not recruiting]
Houston, Texas, United States, 77030
Cancer Care Centers Of South Texas
[Active, not recruiting]
San Antonio, Texas, United States, 78212
United States, Washington
Yakima Valley Memorial Hospital/North Star Lodge
[Completed]
Yakima, Washington, United States, 98902
Argentina
Local Institution
[Active, not recruiting]
Cordoba, Argentina, 5000
Argentina, Buenos Aires
Local Institution
[Active, not recruiting]
Berazategui, Buenos Aires, Argentina, 1880
Local Institution
[Active, not recruiting]
Capital Federal, Buenos Aires, Argentina, 1426
Local Institution
[Active, not recruiting]
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, 1181
Australia, New South Wales
Local Institution
[Active, not recruiting]
Camperdown, New South Wales, Australia, 2050
Australia, Queensland
Local Institution
[Active, not recruiting]
Brisbane, Queensland, Australia, 4102
Australia, South Australia
Local Institution
[Active, not recruiting]
Elizabeth Vale, South Australia, Australia, 5112
Australia, Victoria
Local Institution
[Active, not recruiting]
Fitzroy, Victoria, Australia, 3065
Local Institution
[Active, not recruiting]
Heidelberg, Victoria, Australia, 3084
Austria
Local Institution
[Active, not recruiting]
Wels, Austria, 4600
Local Institution
[Active, not recruiting]
Wien, Austria, 1090
Belgium
Universitair Ziekenhuis Brussel
[Recruiting]
Brussels, Belgium, 1090
Contact:Contact: Lore Decoster, Site 0044 +3224776040
Antwerp University Hospital
[Recruiting]
Edegem, Belgium, 2650
Contact:Contact: Jan Van Meerbeeck, Site 0055 +3238213412
Uz Gent
[Recruiting]
Gent, Belgium, B-9000
Contact:Contact: Veerle Surmont, Site 0056
Uz Leuven
[Recruiting]
Leuven, Belgium, 3000
Contact:Contact: Johan Vansteenkiste, Site 0062 +3216346801
Brazil, Rio Grande Do Sul
Local Institution
[Recruiting]
Ijui, Rio Grande Do Sul, Brazil, 98700
Contact:Contact: Site 0134
Local Institution
[Recruiting]
Porto Alegre, Rio Grande Do Sul, Brazil, 90610
Contact:Contact: Site 0133
Brazil, Sao Paulo
Local Institution
[Recruiting]
Barretos, Sao Paulo, Brazil, 14780
Contact:Contact: Site 0135
Canada, Alberta
Tom Baker Cancer Centre
[Recruiting]
Calgary, Alberta, Canada, T2N 4N2
Contact:Contact: Don G Morris, Site 0086 403-521-3451
Canada, Ontario
Juravinski Cancer Centre
[Recruiting]
Hamilton, Ontario, Canada, L8V 5C2
Contact:Contact: Rosalyn Juergens, Site 0115 905-387-9711 Ext. x64604
Princess Margaret Cancer Centre
[Recruiting]
Toronto, Ontario, Canada, M5G 2M9
Contact:Contact: Natasha Leighl, Site 0113 416-946-4501 Ext. 7890
Canada, Quebec
Chum-Hopital Notre-Dame
[Recruiting]
Montreal, Quebec, Canada, H2L 4M1
Contact:Contact: Normand Blais, Site 0110 514-890-8000 Ext. x24634
Centre De Sante Et De Services Sociaux Rimouski Neigette
[Recruiting]
Rimouski, Quebec, Canada, G5L 5T1
Contact:Contact: Marie-Claude Foley, Site 0109 418-724-3000 Ext. 8029
Czech Republic
Local Institution
[Active, not recruiting]
Olomouc, Czech Republic, 775 20
Local Institution
[Active, not recruiting]
Ostrava - Poruba, Czech Republic, 708 52
Local Institution
[Active, not recruiting]
Praha 8, Czech Republic, 180 81
Local Institution
[Active, not recruiting]
Usti nad Labem, Czech Republic, 401 13
Finland
Local Institution
[Active, not recruiting]
Helsinki, Finland, 00029
Local Institution
[Active, not recruiting]
Tampere, Finland, 33521
Local Institution
[Active, not recruiting]
Vaasa, Finland, 65130
France
Local Institution
[Active, not recruiting]
Caen, France, 14000
Local Institution
[Completed]
Lille, France, 59000
Local Institution
[Active, not recruiting]
Marseille Cedex 20, France, 13915
Local Institution
[Active, not recruiting]
Pontoise Cedex, France, 95303
Local Institution
[Active, not recruiting]
Rennes Cedex 9, France, 35033
Local Institution
[Completed]
Strasbourg, France, 67090
Germany
Sozialstiftung Bamberg
[Active, not recruiting]
Bamberg, Germany, 96049
Klinik Schillerhoehe
[Active, not recruiting]
Gerlingen, Germany, 70839
Krankenhaus Grosshansdorf
[Completed]
Grosshansdorf, Germany, 22927
Thoraxklinik-Heidelberg Ggmbh
[Active, not recruiting]
Heidelberg, Germany, 69126
Local Institution
[Active, not recruiting]
Koeln, Germany, 50937
Local Institution
[Active, not recruiting]
Wiesbaden, Germany, 65199
Greece
Local Institution
[Active, not recruiting]
Athens, Greece, 11527
Greece, Creta
Local Institution
[Active, not recruiting]
Heraklion, Creta, Greece, 71110
Hungary
Local Institution
[Active, not recruiting]
Budapest, Hungary, 1121
Local Institution
[Active, not recruiting]
Debrecen, Hungary, 4032
Local Institution
[Active, not recruiting]
Matrahaza, Hungary, 3233
Italy
Azienda Ospedaliera Moscati
[Active, not recruiting]
Avellino, Italy, 83100
Local Institution
[Active, not recruiting]
Livorno, Italy, 57100
Local Institution
[Active, not recruiting]
Milano, Italy, 20141
Local Institution
[Active, not recruiting]
Napoli, Italy, 80131
Local Institution
[Active, not recruiting]
Perugia, Italy, 06132
Local Institution
[Active, not recruiting]
Terni, Italy, 05100
Japan
Local Institution
[Active, not recruiting]
Akashi, Hyogo, Japan, 673-8558
Local Institution
[Active, not recruiting]
Habikino City, Osaka, Japan, 5838588
Local Institution
[Active, not recruiting]
Kobe, Hyogo, Japan, 6500047
Local Institution
[Active, not recruiting]
Matsuyama, Ehime, Japan, 791-0280
Local Institution
[Active, not recruiting]
Osaka, Japan, 5340027
Local Institution
[Active, not recruiting]
Ota, Gunma, Japan, 3738550
Local Institution
[Active, not recruiting]
Sapporo, Hokkaido, Japan, 062-0931
Local Institution
[Active, not recruiting]
Tokyo, Japan, 1358550
Local Institution
[Active, not recruiting]
Wakayama, Japan, 641-8510
Japan, Aichi
Local Institution
[Active, not recruiting]
Nagoya, Aichi, Japan, 4600001
Local Institution
[Active, not recruiting]
Nagoya, Aichi, Japan, 4648681
Japan, Miyagi
Local Institution
[Active, not recruiting]
Natori-shi, Miyagi, Japan, 9811293
Japan, Niigata
Local Institution
[Active, not recruiting]
Niigata-shi, Niigata, Japan, 9518566
Japan, Osaka
Local Institution
[Completed]
Osaka-Sayama-Shi, Osaka, Japan, 5898511
Local Institution
[Active, not recruiting]
Sakai, Osaka, Japan, 591-8555
Japan, Saitama
Local Institution
[Active, not recruiting]
Kitaadachi-gun, Saitama, Japan, 3620806
Japan, Shizuoka
Local Institution
[Active, not recruiting]
Sunto-gun, Shizuoka, Japan, 4118777
Japan, Tokyo
Local Institution
[Active, not recruiting]
Chuo-ku, Tokyo, Japan, 1040045
Korea, Republic of
Local Institution
[Active, not recruiting]
Seoul, Korea, Republic of, 120-752
Local Institution
[Active, not recruiting]
Seoul, Korea, Republic of, 135-710
Local Institution
[Active, not recruiting]
Seoul, Korea, Republic of, 138-736
Mexico, Distrito Federal
Local Institution
[Active, not recruiting]
Mexico City, Distrito Federal, Mexico, 14080
Mexico, Jalisco
Local Institution
[Active, not recruiting]
Guadalajara, Jalisco, Mexico, 44280
Mexico, Yucatan
Local Institution
[Completed]
Merida, Yucatan, Mexico, 97133
Netherlands
Antoni Van Leeuwenhoek Ziekenhuis
[Recruiting]
Amsterdam, Netherlands, 1066 CX
Contact:Contact: Michel Van Den Heuvel, Site 0045 +31205122958
Umcg, Universitair Medisch Centrum Groningen
[Recruiting]
Groningen, Netherlands, 9713 GZ
Contact:Contact: Tjn Hiltermann, Site 0057 +31503612357
Local Institution
[Recruiting]
Rotterdam, Netherlands, 3015 CE
Contact:Contact: Site 0046
Poland
Local Institution
[Active, not recruiting]
Bydgoszcz, Poland, 85-796
Local Institution
[Active, not recruiting]
Krakow, Poland, 31-202
Local Institution
[Active, not recruiting]
Lodz, Poland, 93-513
Local Institution
[Active, not recruiting]
Warszawa, Poland, 02-781
Local Institution
[Active, not recruiting]
Wodzislaw Slaski, Poland, 44-300
Romania
Local Institution
[Active, not recruiting]
Cluj Napoca, Romania, 400015
Local Institution
[Active, not recruiting]
Cluj-napoca, Romania, 400352
Local Institution
[Active, not recruiting]
Ploiesti, Romania, 100337
Spain
Local Institution
[Active, not recruiting]
Barcelona, Spain, 08035
Local Institution
[Active, not recruiting]
Las Palmas De Gran Canaria, Spain, 35016
Local Institution
[Active, not recruiting]
Madrid, Spain, 28050
Local Institution
[Active, not recruiting]
Malaga, Spain, 29010
Local Institution
[Completed]
Sevilla, Spain, 41013
Local Institution
[Active, not recruiting]
Valencia, Spain, 46014
Sweden
Local Institution
[Completed]
Stockholm, Sweden, 171 76
Local Institution
[Active, not recruiting]
Uppsala, Sweden, 751 85
Switzerland
Local Institution
[Active, not recruiting]
Chur, Switzerland, 7000
Local Institution
[Active, not recruiting]
Lausanne, Switzerland, 1011
Local Institution
[Completed]
Zuerich, Switzerland, 8091
Taiwan
Local Institution
[Not yet recruiting]
Taipei, Taiwan, 100
Contact:Contact: Site 0156
Local Institution
[Active, not recruiting]
Taipei, Taiwan, 11217
Turkey
Local Institution
[Active, not recruiting]
Kayseri, Turkey, 38039
United Kingdom, Greater London
North Middlesex University Hospital
[Recruiting]
London, Greater London, United Kingdom, N18 1QX
Contact:Contact: David Chao, Site 0098 +442088872687
United Kingdom, Greater Manchester
Christie Hospital Nhs Trust
[Recruiting]
Manchester, Greater Manchester, United Kingdom, M20 4XB
Contact:Contact: Yvonne Summers, Site 0097 +441619187470
United Kingdom, Yorkshire
St James'S University Hospital
[Recruiting]
Leeds, Yorkshire, United Kingdom, LS9 7TF
Contact:Contact: Clive Mulatero, Site 0053 +441132067903
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Links: Description: BMS clinical trial educational resource
Available IPD/Information:
Scroll up to access the controls Scroll to the Study top
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services